It is currently Fri Feb 27, 2015 6:10 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

RE COLD MICROPATICLES LEAD TO SPMS THERAPY

HI Friends Newszealand and Australian based companies designed and manufactured a micropaticiles can be used fight SPMS AND CANCERS
Read more attached
http://multiplesclerosisnewstoday.com/2 ... ign=buffer
regards
seeva
Read more : RE COLD MICROPATICLES LEAD TO SPMS THERAPY | Views : 140 | Replies : 0


MCC 950 MS Progress from Older Drug

I heard about this drug yesterday (Feb 18) which was discovered by scientists at the University of Queensland.

They worked with an international team to develop a molecule that fights one of the main causes of inflammatory diseases, a breakthrough researchers say could lead to safer and cheaper treatments.

Alzheimer's, arthritis and multiple sclerosis treatments could be improved by Queensland scientists' development of MCC950 molecule

MCC950 is a potent and specific inhibitor of the NLRP3 ...
Read more : MCC 950 MS Progress from Older Drug | Views : 330 | Replies : 0




Opinions on NDC-1308?

This is exciting stuff I've read. Any opinions on this drug?
Read more : Opinions on NDC-1308? | Views : 154 | Replies : 0


Alkermes reports positive data on multiple sclerosis drug

Alkermes reports positive data on multiple sclerosis drug ALKS 8700

Alkermes plc has reported positive top-line data from a phase I study on its experimental MS drug, ALKS 8700. ALKS 8700 is a novel monomethyl fumarate (MMF) molecule being developed for the treatment of MS..... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Alkermes reports positive data on multiple sclerosis drug | Views : 308 | Replies : 0




Could anatabine citrate be a used as a MS therapy?

Drug development company Rock Creek Pharmaceuticals has announced a new clinical trial application with the Medicines Healthcare Products Regulatory Agency (MHRA) has been approved. The company is set to proceed with a Phase I study of Anatabine Citrate, a chemical that is found naturally in aubergine, potatoes, green tomatoes and other members of the Solanaceae family of plants, as well as in tobacco and tobacco smoke. The chemical is known for its anti-inflammatory properties unique ...
Read more : Could anatabine citrate be a used as a MS therapy? | Views : 344 | Replies : 1


Phase I trial data for remyelinating antibody in MS released

Acorda Therapeutics has today announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. The trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied. Based on this, the Company intends to advance clinical development of rHIgM22..... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Phase I trial data for remyelinating antibody in MS released | Views : 304 | Replies : 0


Primary & secondary progressive MS drug progress update

MedDay, a biotechnology company that develops new drugs for nervous system disorders, announced an update on the progress of its development pipeline with its lead product MD1003 for the treatment of primary and secondary progressive multiple sclerosis (MS). The first study is expected to be complete in early 2015, while the second should be complete in late 2015....... Read More - http://www.ms-uk.org/emergingtherapies
Read more : Primary & secondary progressive MS drug progress update | Views : 443 | Replies : 0


Results from phase1b APD334 for autoimmune diseases released

Arena Pharmaceuticals, Inc. released the first results from its phase 1b trial that for the evaluation of an oral drug candidate called APD334 for the treatment of autoimmune diseases, such as multiple sclerosis (MS). The multiple ascending dose clinical trial demonstrated encouraging findings about the drug, which is designed to target the sphingosine 1-phosphate subtype 1 (S1P1) receptor............ Read More - http://www.ms-uk.org/emergingtherapies
Read more : Results from phase1b APD334 for autoimmune diseases released | Views : 323 | Replies : 0


 

Login  •  Register


Statistics

Total posts 223871 • Total topics 23316 • Total members 14752


Contact us | Terms of Service